$LPCN
Lipocine Inc.

2013 Form 10-K Financial Statement

#000114420414019291 Filed on March 31, 2014

View on sec.gov

Income Statement

Concept 2013 2012 Q4 2012
Revenue $0.00 $0.00 $7.710M
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.640M $0.00 $80.00K
YoY Change 4450.0% -100.0% 700.0%
% of Gross Profit
Research & Development $5.123M $2.281M
YoY Change 124.57%
% of Gross Profit
Depreciation & Amortization $20.00K
YoY Change
% of Gross Profit
Operating Expenses $10.68M $0.00 $3.832M
YoY Change 178.77% -100.0% 38223.95%
Operating Profit -$10.68M $3.877M
YoY Change -375.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $40.00K
YoY Change
Pretax Income -$10.65M $0.00 $3.888M
YoY Change -373.82% -100.0% -38975.89%
Income Tax -$55.05K $0.00 $684.00
% Of Pretax Income 0.02%
Net Earnings -$10.59M $0.00 $3.887M
YoY Change -372.46% -100.0% -38969.05%
Net Earnings / Revenue 50.42%
Basic Earnings Per Share -$1.44 $0.85
Diluted Earnings Per Share -$1.44 $0.00 $0.85
COMMON SHARES
Basic Shares Outstanding 7.363M shares 4.456M shares
Diluted Shares Outstanding 7.363M shares 4.456M shares

Balance Sheet

Concept 2013 2012 Q4 2012
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.26M $0.00 $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents $45.26M $5.377M $0.00
Short-Term Investments
Other Short-Term Assets $770.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $46.03M $5.472M $0.00
YoY Change 18139.54% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment $30.00K $49.36K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.00K $45.00K
YoY Change
Total Long-Term Assets $80.00K $94.36K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $46.03M $5.472M $0.00
Total Long-Term Assets $80.00K $94.36K $0.00
Total Assets $46.11M $5.566M $0.00
YoY Change 18454.06% -100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.030M $87.03K $10.00K
YoY Change 10200.0% 770.27% 0.0%
Accrued Expenses $260.0K $108.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.280M $212.8K $10.00K
YoY Change 12700.0% 2028.13% 0.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.280M $212.8K $10.00K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.280M $250.0K $10.00K
YoY Change 12700.0% 2400.25% 0.0%
SHAREHOLDERS EQUITY
Retained Earnings -$37.27M
YoY Change
Common Stock $446.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.82M $5.316M -$10.00K
YoY Change
Total Liabilities & Shareholders Equity $46.11M $5.566M $0.00
YoY Change 18454.06% -100.0%

Cashflow Statement

Concept 2013 2012 Q4 2012
OPERATING ACTIVITIES
Net Income -$10.59M $0.00 $3.887M
YoY Change -372.46% -100.0% -38969.05%
Depreciation, Depletion And Amortization $20.00K
YoY Change
Cash From Operating Activities -$8.588M $2.080M -$3.178M
YoY Change 170.21% -20900.0% 31683.93%
INVESTING ACTIVITIES
Capital Expenditures $1.206K $12.32K
YoY Change -90.21%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$1.206K $10.00K -$12.32K
YoY Change -90.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.52M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $48.48M 40.00K $0.00
YoY Change 33.33% -100.0%
NET CHANGE
Cash From Operating Activities -$8.588M 2.080M -$3.178M
Cash From Investing Activities -$1.206K 10.00K -$12.32K
Cash From Financing Activities $48.48M 40.00K $0.00
Net Change In Cash $39.89M 2.130M -$3.191M
YoY Change -1350.09% 10550.0% -16053.55%
FREE CASH FLOW
Cash From Operating Activities -$8.588M $2.080M -$3.178M
Capital Expenditures $1.206K $12.32K
Free Cash Flow -$8.590M -$3.191M
YoY Change 169.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5377114 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90934 USD
CY2012Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
3815 USD
CY2013Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
46033728 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28794 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000 USD
CY2013Q4 us-gaap Assets
Assets
46107522 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
92686881 USD
CY2012Q4 us-gaap Liabilities
Liabilities
250025 USD
CY2013Q4 us-gaap Liabilities
Liabilities
1283775 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1267 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
446 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42590042 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
256754 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
212813 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
5316193 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5566218 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37274295 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1283775 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47864401 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
44823747 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46107522 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1027021 USD
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
17836 USD
CY2013Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 USD
CY2012Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
37212 USD
CY2013Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
0 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
247841 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
247841 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
348000 USD
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
356000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21767 USD
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4455790 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12668393 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4455790 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12668393 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
946281 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
354027 shares
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3761 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
8610 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
23592 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1264345 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
915627 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.07
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.29
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.81
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.53
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.25
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.84
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M24D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M24D
CY2003Q4 lpcn Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
20467 shares
CY2003Q4 lpcn Class Of Warrant Or Right Exercise Price Of Warrants Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsIssued
12.21
CY2003Q4 lpcn Class Of Warrant Or Right Amended Expiration Date
ClassOfWarrantOrRightAmendedExpirationDate
2015-12-31
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the Company modified the vesting terms for its unvested performance based stock options and unvested restricted common stock of fifteen employees and non-employee directorsto vest on the earlier of the first closing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015.
CY2012 us-gaap License And Services Revenue
LicenseAndServicesRevenue
7523438 USD
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0 USD
CY2012 lpcn Research Revenue
ResearchRevenue
186233 USD
CY2013 lpcn Research Revenue
ResearchRevenue
0 USD
CY2012 us-gaap Revenues
Revenues
7709671 USD
CY2013 us-gaap Revenues
Revenues
0 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2281196 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5122864 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1551199 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3635690 USD
CY2012 lpcn Reverse Merger Costs
ReverseMergerCosts
0 USD
CY2013 lpcn Reverse Merger Costs
ReverseMergerCosts
1011630 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
3877276 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10683630 USD
CY2012 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
10313 USD
CY2013 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
38476 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3887589 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10645154 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
684 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-55048 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
3886905 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-10590106 USD
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4455790 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7363076 shares
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4455790 shares
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7363076 shares
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
42566 USD
CY2012 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
CY2013 us-gaap Other Noncash Expense
OtherNoncashExpense
3815 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
127488 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
979151 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-313753 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4732 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
679096 USD
CY2012 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-4676 USD
CY2013 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
0 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-60131 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
668811 USD
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
24371 USD
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
148804 USD
CY2012 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
684 USD
CY2013 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-55048 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7523437 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3178393 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8588456 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12316 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1206 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12316 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1206 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10575 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12809126 USD
CY2012 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
0 USD
CY2013 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
53100 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3190709 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39886584 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8567823 USD
CY2012 lpcn Accured Common Stock Offering Costs
AccuredCommonStockOfferingCosts
0 USD
CY2013 lpcn Accured Common Stock Offering Costs
AccuredCommonStockOfferingCosts
271183 USD
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Trading Symbol
TradingSymbol
LPCN
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12772177 shares
CY2013 dei Entity Registrant Name
EntityRegistrantName
Lipocine Inc.
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001535955
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q3 dei Entity Public Float
EntityPublicFloat
42200000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
1301800 USD
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 24.45pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 24.5pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><strong><i>(a)<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></i></strong></div> </td> <td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</i></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 48.95pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include those related to revenue recognition; stock-based compensation; valuation of deferred taxes; income tax uncertainties; and the useful lives of property and equipment.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
127488 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
979151 USD
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 0in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> </td> <td style="WIDTH: 24.5pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><b>(1)</b></div> </td> <td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><b>Description of Business</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.45pt" align="left"><font style="FONT-SIZE: 10pt">Lipocine Inc. (&#8220;Lipocine&#8221; or the&#160;&#8220;Company&#8221;) is engaged in research and development for the delivery of drugs using its proprietary delivery technology. The Company&#8217;s principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its own drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The Company has funded operating costs primarily through collaborative license, milestone and research arrangements, through federal grants and through the sale of equity securities. The Company is incorporated under the laws of the State of Delaware.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q3 lpcn Percentage Of Fee To Be Received
PercentageOfFeeToBeReceived
0.2 pure
CY2013Q3 lpcn Description Of Terms Of Service Agreement
DescriptionOfTermsOfServiceAgreement
Under the service agreement, the Company will provide facilities and up to 10 percent of the services of certain employees to Spriaso for a period of up to 18 months.
CY2013Q3 lpcn Maximum Proceeds From Affiliates Under License Agreement
MaximumProceedsFromAffiliatesUnderLicenseAgreement
10000000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1321780 USD
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3619353 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1365408 USD
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-493355 USD
CY2012 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2013 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
394803 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
66 USD
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
66 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
32336 USD
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
85270 USD
CY2012 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
11910 USD
CY2013 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-46515 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
859095 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1152904 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
9216044 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
10041416 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
38927 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
59505 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
17635 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
0 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1210405 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
410490 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
280872 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
0 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11622978 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11664315 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11619578 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11660247 USD
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3400 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4068 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3400 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
4068 USD
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3400 USD
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4068 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
28304 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
28304 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
35549 USD
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
36755 USD
CY2012Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
960044 USD
CY2013Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
960044 USD
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
51404 USD
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
51404 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1046997 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1048203 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
997642 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1019409 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
127488 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
979151 USD
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M17D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0138 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6827 pure
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2686727 USD
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1933480 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3801696 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10590106 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
3801696 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10590106 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1500000 USD
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
41000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
9000 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2012 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
1000 USD
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 USD
CY2012Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2700000 USD
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1900000 USD
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.92
CY2013 us-gaap Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
85209 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
584 USD
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-55148 USD
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
100 USD
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
100 USD
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
684 USD
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-55048 USD
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
584 USD
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-55148 USD
CY2012 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100 USD
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
3832395 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
10683630 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3886905 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10590106 USD
CY2012 lpcn Proceeds From Issuance Of Pipe Common Stock
ProceedsFromIssuanceOfPipeCommonStock
0 USD
CY2013 lpcn Proceeds From Issuance Of Pipe Common Stock
ProceedsFromIssuanceOfPipeCommonStock
35709645 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48476246 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10575 USD
CY2013 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
53100 USD
CY2013 lpcn Stock Issued During Period Value Issued In Private Offering
StockIssuedDuringPeriodValueIssuedInPrivateOffering
35709645 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12537943 USD
CY2013 lpcn Operating Loss Carryforwards Limitations On Use Amount
OperatingLossCarryforwardsLimitationsOnUseAmount
1100000 USD
CY2013 lpcn Operating Loss Carryforwards Preownership Change Amount
OperatingLossCarryforwardsPreownershipChangeAmount
20200000 USD
CY2013 lpcn Operating Loss Forgive Preownership Change Amount
OperatingLossForgivePreownershipChangeAmount
6200000 USD
CY2013 lpcn Tax Credit Carryforward Preownership Change Amount
TaxCreditCarryforwardPreownershipChangeAmount
1200000 USD
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P10M28D
CY2013 lpcn Stock Issued During Period Value Issued In Settlement For Termination Of Certain Rights In Stock Purchase Agreement
StockIssuedDuringPeriodValueIssuedInSettlementForTerminationOfCertainRightsInStockPurchaseAgreement
913446 USD
CY2012 lpcn Settlement Expenses
SettlementExpenses
0 USD
CY2013 lpcn Settlement Expenses
SettlementExpenses
913446 USD
CY2012 lpcn Income Tax Rate Reconciliation Loss Of Tax Attributes Due To Change In Ownership
IncomeTaxRateReconciliationLossOfTaxAttributesDueToChangeInOwnership
0 USD
CY2013 lpcn Income Tax Rate Reconciliation Loss Of Tax Attributes Due To Change In Ownership
IncomeTaxRateReconciliationLossOfTaxAttributesDueToChangeInOwnership
3540653 USD
CY2012 lpcn Income Tax Rate Reconciliation Settlement For Termination Of Stock Rights
IncomeTaxRateReconciliationSettlementForTerminationOfStockRights
0 USD
CY2013 lpcn Income Tax Rate Reconciliation Settlement For Termination Of Stock Rights
IncomeTaxRateReconciliationSettlementForTerminationOfStockRights
310572 USD
CY2012 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
227189 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6330494 USD
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4960933 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12000 USD

Files In Submission

Name View Source Status
0001144204-14-019291-index-headers.html Edgar Link pending
0001144204-14-019291-index.html Edgar Link pending
0001144204-14-019291.txt Edgar Link pending
0001144204-14-019291-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lpcn-20131231.xml Edgar Link completed
lpcn-20131231.xsd Edgar Link pending
lpcn-20131231_cal.xml Edgar Link unprocessable
lpcn-20131231_def.xml Edgar Link unprocessable
lpcn-20131231_lab.xml Edgar Link unprocessable
lpcn-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v369971_10k.htm Edgar Link pending
v369971_ex10-4.htm Edgar Link pending
v369971_ex21-1.htm Edgar Link pending
v369971_ex31-1.htm Edgar Link pending
v369971_ex31-2.htm Edgar Link pending
v369971_ex32-1.htm Edgar Link pending
v369971_ex32-2.htm Edgar Link pending